Emodin alleviates renal fibrosis by targeting the ALKBH1/m5C axis to sustain TRPV4 expression and inhibit TGF-β1/Smad2/3 signaling
Toxicology and Applied Pharmacology · 2026-09 · 514 · 117889
DOI: 10.1016/j.taap.2026.117889 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxicology and Applied Pharmacology, 2026-09. Verfasst von Yan Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Traditional Chinese Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: TRPV Cation Channels, Emodin, Transforming Growth Factor beta1, Kidney. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Natural Science Basic Research Program of Shaanxi Province.
Abstract (Originalsprache)
Renal fibrosis is the hallmark pathological outcome of chronic kidney disease (CKD), and effective anti-fibrotic therapies remain scarce. This study investigates the renoprotective effects and underlying mechanisms of emodin. A rat model of renal fibrosis was established using doxorubicin hydrochloride (DXR, 4 mg/kg), and NRK-52E cells were treated with angiotensin II (Ang II, 1 μM) to induce renal fibrosis in vitro. The regulatory effects of emodin (oral gavage of 40 mg/kg/day for 4 weeks in vivo and 100 μmol/L in vitro) on renal dysfunction, fibrosis, oxidative stress, and pyroptosis were evaluated. Additionally, the role of emodin in mediating the 5-methylcytosine (m5C) modification of transient receptor potential vanilloid 4 (TRPV4) was investigated in vitro. The interaction between emodin and the m5C regulatory protein AlkB homolog 1 (ALKBH1), as well as the association between ALKBH1 and TRPV4 mRNA, were detected. Emodin significantly ameliorated renal dysfunction and attenuated fibrosis in DXR-induced rats. Emodin also restored TRPV4 expression, which was downregulated in the fibrotic models. Conversely, TRPV4 knockdown partially reversed the protective effects of emodin, leading to exacerbated activation of the transforming growth factor-β1 (TGF-β1)/Smad2/3 pathway, along with enhanced fibrosis and pyroptosis. Mechanistically, Ang II elevated global m5C RNA modification and upregulated the demethylase ALKBH1; these effects were reversed by emodin. Furthermore, ALKBH1 overexpression promoted the destabilization of TRPV4 mRNA via site-specific m5C demethylation. Emodin alleviates renal fibrosis by preserving TRPV4 expression through targeting the ALKBH1-dependent m5C demethylation axis. Targeting the ALKBH1-m5C-TRPV4 axis may represent a promising therapeutic strategy for renal fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Traditional Chinese Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
- Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, China; Department of Nephrology, Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xianyang, Shaanxi, China.
- Department of Traditional Chinese Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China. Electronic address: NL20150312@163.com.
Förderung
- Natural Science Basic Research Program of Shaanxi Province
Zitieren
APA
Liu, Y., Sun, X., Sun, W., & Li, R. (2026). Emodin alleviates renal fibrosis by targeting the ALKBH1/m5C axis to sustain TRPV4 expression and inhibit TGF-β1/Smad2/3 signaling. Toxicology and Applied Pharmacology, 514, 117889. https://doi.org/10.1016/j.taap.2026.117889
Vancouver
Liu Y, Sun X, Sun W, Li R. Emodin alleviates renal fibrosis by targeting the ALKBH1/m5C axis to sustain TRPV4 expression and inhibit TGF-β1/Smad2/3 signaling. Toxicology and Applied Pharmacology. 2026;514:117889. doi:10.1016/j.taap.2026.117889
BibTeX
@article{Liu2026,
author = {Liu, Yan and Sun, Xi and Sun, Wansen and Li, Ruiping},
title = {Emodin alleviates renal fibrosis by targeting the ALKBH1/m5C axis to sustain TRPV4 expression and inhibit TGF-β1/Smad2/3 signaling},
journal = {Toxicology and Applied Pharmacology},
year = {2026},
volume = {514},
pages = {117889},
doi = {10.1016/j.taap.2026.117889}
}
EUVIMED